Long-Term Risk of Clinical Progression After Biochemical Recurrence Following Radical Prostatectomy: The Impact of Time from Surgery to Recurrence (Q51050747)

From Wikidata

Jump to navigation Jump to search

scientific article published on February 22, 2011

Language	Label	Description	Also known as
English	Long-Term Risk of Clinical Progression After Biochemical Recurrence Following Radical Prostatectomy: The Impact of Time from Surgery to Recurrence	scientific article published on February 22, 2011

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

27 March 2018

http://europepmc.org/abstract/MED/21388736

Long-term risk of clinical progression after biochemical recurrence following radical prostatectomy: the impact of time from surgery to recurrence (English)

1 reference

Europe PubMed Central

PubMed publication ID

27 March 2018

http://europepmc.org/abstract/MED/21388736

Long-Term Risk of Clinical Progression After Biochemical Recurrence Following Radical Prostatectomy: The Impact of Time from Surgery to Recurrence (English)

1 reference

10.1016/J.EURURO.2011.02.026

https://api.crossref.org/works/10.1016/J.EURURO.2011.02.026

26 November 2024

local neoplasm recurrence

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21388736

26 November 2024

Robert Jeffrey Karnes

7

object named as

R Jeffrey Karnes

1 reference

Europe PubMed Central

PubMed publication ID

27 March 2018

http://europepmc.org/abstract/MED/21388736

author name string

Stephen A. Boorjian

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21388736

26 November 2024

R. Houston Thompson

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21388736

26 November 2024

Matthew K. Tollefson

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21388736

26 November 2024

Laureano J. Rangel

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21388736

26 November 2024

Eric J. Bergstralh

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21388736

26 November 2024

Michael L. Blute

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21388736

26 November 2024

language of work or name

0 references

publication date

22 February 2011

1 reference

Europe PubMed Central

PubMed publication ID

27 March 2018

http://europepmc.org/abstract/MED/21388736

full work available at URL

https://api.elsevier.com/content/article/PII:S0302283811001588?httpAccept=text/plain

1 reference

10.1016/J.EURURO.2011.02.026

https://api.crossref.org/works/10.1016/J.EURURO.2011.02.026

26 November 2024

https://api.elsevier.com/content/article/PII:S0302283811001588?httpAccept=text/xml

1 reference

10.1016/J.EURURO.2011.02.026

https://api.crossref.org/works/10.1016/J.EURURO.2011.02.026

26 November 2024

European Urology

1 reference

Europe PubMed Central

PubMed publication ID

27 March 2018

http://europepmc.org/abstract/MED/21388736

59

1 reference

Europe PubMed Central

PubMed publication ID

27 March 2018

http://europepmc.org/abstract/MED/21388736

6

1 reference

Europe PubMed Central

PubMed publication ID

27 March 2018

http://europepmc.org/abstract/MED/21388736

893-899

1 reference

Europe PubMed Central

PubMed publication ID

27 March 2018

http://europepmc.org/abstract/MED/21388736

The Long-Term Clinical Impact of Biochemical Recurrence of Prostate Cancer 5 or More Years After Radical Prostatectomy

1

1 reference

10.1016/J.EURURO.2011.02.026

https://api.crossref.org/works/10.1016/J.EURURO.2011.02.026

26 November 2024

Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience

2

1 reference

10.1016/J.EURURO.2011.02.026

https://api.crossref.org/works/10.1016/J.EURURO.2011.02.026

26 November 2024

Rising prostate-specific antigen after primary prostate cancer therapy

3

1 reference

10.1016/J.EURURO.2011.02.026

https://api.crossref.org/works/10.1016/J.EURURO.2011.02.026

26 November 2024

Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results

4

1 reference

10.1016/J.EURURO.2011.02.026

https://api.crossref.org/works/10.1016/J.EURURO.2011.02.026

26 November 2024

Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy

5

1 reference

10.1016/J.EURURO.2011.02.026

https://api.crossref.org/works/10.1016/J.EURURO.2011.02.026

26 November 2024

Treatment failure after primary and salvage therapy for prostate cancer: likelihood, patterns of care, and outcomes.

6

1 reference

10.1016/J.EURURO.2011.02.026

https://api.crossref.org/works/10.1016/J.EURURO.2011.02.026

26 November 2024

Patterns of secondary cancer treatment for biochemical failure following radical prostatectomy: data from CaPSURE.

7

1 reference

10.1016/J.EURURO.2011.02.026

https://api.crossref.org/works/10.1016/J.EURURO.2011.02.026

26 November 2024

Natural history of progression after PSA elevation following radical prostatectomy

8

1 reference

10.1016/J.EURURO.2011.02.026

https://api.crossref.org/works/10.1016/J.EURURO.2011.02.026

26 November 2024

Predictors of prostate cancer-specific mortality after radical prostatectomy or radiation therapy

9

1 reference

10.1016/J.EURURO.2011.02.026

https://api.crossref.org/works/10.1016/J.EURURO.2011.02.026

26 November 2024

Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer

10

1 reference

10.1016/J.EURURO.2011.02.026

https://api.crossref.org/works/10.1016/J.EURURO.2011.02.026

26 November 2024

Radical prostatectomy: long-term cancer control and recovery of sexual and urinary function ("trifecta")

11

1 reference

10.1016/J.EURURO.2011.02.026

https://api.crossref.org/works/10.1016/J.EURURO.2011.02.026

26 November 2024

Time to prostate specific antigen recurrence after radical prostatectomy and risk of prostate cancer specific mortality

13

1 reference

10.1016/J.EURURO.2011.02.026

https://api.crossref.org/works/10.1016/J.EURURO.2011.02.026

26 November 2024

Predictors of secondary treatment following biochemical recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital database

14

1 reference

10.1016/J.EURURO.2011.02.026

https://api.crossref.org/works/10.1016/J.EURURO.2011.02.026

26 November 2024

Defining Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy: A Proposal for a Standardized Definition

16

1 reference

10.1016/J.EURURO.2011.02.026

https://api.crossref.org/works/10.1016/J.EURURO.2011.02.026

26 November 2024

Estimation of failure probabilities in the presence of competing risks: new representations of old estimators

18

1 reference

10.1016/J.EURURO.2011.02.026

https://api.crossref.org/works/10.1016/J.EURURO.2011.02.026

26 November 2024

Long-term outcome after radical prostatectomy for patients with lymph node positive prostate cancer in the prostate specific antigen era

19

1 reference

10.1016/J.EURURO.2011.02.026

https://api.crossref.org/works/10.1016/J.EURURO.2011.02.026

26 November 2024

Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy

20

1 reference

10.1016/J.EURURO.2011.02.026

https://api.crossref.org/works/10.1016/J.EURURO.2011.02.026

26 November 2024

Death in patients with recurrent prostate cancer after radical prostatectomy: prostate-specific antigen doubling time subgroups and their associated contributions to all-cause mortality

21

1 reference

10.1016/J.EURURO.2011.02.026

https://api.crossref.org/works/10.1016/J.EURURO.2011.02.026

26 November 2024

Impact of patient age at treatment on outcome following radical retropubic prostatectomy for prostate cancer.

22

1 reference

10.1016/J.EURURO.2011.02.026

https://api.crossref.org/works/10.1016/J.EURURO.2011.02.026

26 November 2024

Radical prostatectomy in men aged >or=70 years: effect of age on upgrading, upstaging, and the accuracy of a preoperative nomogram

23

1 reference

10.1016/J.EURURO.2011.02.026

https://api.crossref.org/works/10.1016/J.EURURO.2011.02.026

26 November 2024

High risk biochemical relapse and the timing of androgen deprivation therapy

24

1 reference

10.1016/J.EURURO.2011.02.026

https://api.crossref.org/works/10.1016/J.EURURO.2011.02.026

26 November 2024

Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy

25

1 reference

10.1016/J.EURURO.2011.02.026

https://api.crossref.org/works/10.1016/J.EURURO.2011.02.026

26 November 2024

Timing of androgen deprivation therapy and its impact on survival after radical prostatectomy: a matched cohort study

26

1 reference

10.1016/J.EURURO.2011.02.026

https://api.crossref.org/works/10.1016/J.EURURO.2011.02.026

26 November 2024

Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy

27

1 reference

10.1016/J.EURURO.2011.02.026

https://api.crossref.org/works/10.1016/J.EURURO.2011.02.026

26 November 2024

Radiation therapy after radical prostatectomy: impact on metastasis and survival

28

1 reference

10.1016/J.EURURO.2011.02.026

https://api.crossref.org/works/10.1016/J.EURURO.2011.02.026

26 November 2024

Re: Radiation therapy after radical prostatectomy: impact on metastasis and survival S. A. Boorjian, R. J. Karnes, P. L. Crispen, L. J. Rangel, E. J. Bergstralh and M. L. Blute J Urol 2009; 182: 2708-2715.

29

1 reference

10.1016/J.EURURO.2011.02.026

https://api.crossref.org/works/10.1016/J.EURURO.2011.02.026

26 November 2024

Identifiers

10.1016/J.EURURO.2011.02.026

1 reference

Europe PubMed Central

PubMed publication ID

27 March 2018

http://europepmc.org/abstract/MED/21388736

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

27 March 2018

http://europepmc.org/abstract/MED/21388736

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q51050747&oldid=2280101389"